Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Transcenta Holding Limited ( (HK:6628) ) is now available.
Transcenta Holding Limited announced promising new data from its Phase II trial of Osemitamab (TST001) for advanced gastric or gastroesophageal junction cancer, presented at the 2025 ASCO Annual Meeting. The trial results indicate significant survival benefits, with a median overall survival of 20.4 months for all patients and 21.7 months for those with higher CLDN18.2 expression. These findings strengthen the company’s commitment to advancing this treatment, potentially improving patient outcomes and enhancing its position in the oncology market.
More about Transcenta Holding Limited
Transcenta Holding Limited operates in the biotechnology industry, focusing on the development of innovative antibody-based therapeutics. The company is particularly involved in creating treatments targeting cancer, with a market focus on gastric or gastroesophageal junction (G/GEJ) and pancreatic cancers.
Average Trading Volume: 1,218,151
Technical Sentiment Signal: Hold
Current Market Cap: HK$692.1M
For an in-depth examination of 6628 stock, go to TipRanks’ Stock Analysis page.